Novartis Friday announced results from a head-to-head trial of its secukinumab (Cosentyx) versus adalimumab in patients with active psoriatic arthritis (PsA), saying its therapy missed statistical significance for its primary end point.
Novartis Friday announced results from a head-to-head trial of its secukinumab (Cosentyx) versus adalimumab in patients with active psoriatic arthritis (PsA), saying its therapy missed statistical significance for its primary end point.
The interleukin-17 (IL-17) inhibitor is already approved to treat ankylosing spondylitis, PsA, and plaque psoriasis.
Although secukinumab missed showing superiority for American College of Rheumatology criteria for 20% improvement (ACR20) at week 52, the company said it showed numerical superiority.
In the EXCEED trial comparing secukinumab to adalimumab, PsA-specific end points were seen in a pre-specified sensitivity analysis. No new safety signals were detected, with results showing a consistent and favorable safety profile for secukinumab, similar to previous trials.
EXCEED, the first double-blinded head-to-head clinical trial evaluating secukinumab at a dose of 300 mg versus adalimumab at a dose of 40 mg, is a 52-week, multicenter, randomized, double-blind, active control, Phase 3b trial evaluating the efficacy of secukinumab compared with adalimumab in over 800 patients with active PsA who are naïve to biologics.
Secukinumab was administered at baseline, weeks 1-4, and then every 4 weeks until week 48. Adalimumab 40 mg was administered at baseline, and then every 2 weeks until week 50.
Secukinumab has less frequent dosing than adalimumab, which won’t face biosimilar competition until 2023, although other therapies, such as oral agents as well as other injectable competitors are waiting in line.
“These data will be welcomed by patients and clinicians to guide clinical decision making and highlight secukinumab as a viable option as a first-line biologic for the treatment of psoriatic arthritis,” says Iain McInnes, a professor of rheumatology at the University of Glasgow and an investigator in the secukinumab clinical trial program.
“EXCEED is the first ever monotherapy head-to-head trial with a primary end point in psoriatic arthritis specific to joints.” said Eric Hughes, global development unit head, Immunology, Hepatology & Dermatology. “We will assess the EXCEED data in their totality and we view the results as confirming our vision of Cosentyx becoming standard of care in psoriatic arthritis.”
Detailed data will be presented at a future scientific congress.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.